title: Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France.
abstract: BACKGROUND
  Data regarding the prevalence of hepatitis C (HCV) and hepatitis B (HBV) in inflammatory bowel disease (IBD) patients are conflicting.
  
  
  METHODS
  In all, 315 IBD (252 Crohn's disease [CD] and 63 ulcerative colitis [UC]) patients were consecutively recruited between June 2005 and May 2009.
  
  
  RESULTS
  The median age was 33 years (interquartile range [IQR]: 24-43) and median disease duration was 5 years (IQR: 2-11). Present and/or past HBV and HCV infection was found in 2.86% of 315 patients (CD: HBsAg 0.79%, anti-HBc 2.78%, anti-HCV 0.79%; UC: HBsAg 1.59%, anti-HBc 1.59%, anti-HCV 1.59%). Effective vaccination (anti-HBs without anti-HBc) was present in 48.9% of 315 patients. In multivariate analysis, age at diagnosis over 31 years (odds ratio [OR] 0.29; 95% confidence interval [CI] 0.15-0.58; P = 0.005), disease duration over 7 years (OR 0.43; 95% CI 0.23-0.83; P = 0.005), age at inclusion over 33 years (OR 0.44; 95% CI 0.20-0.94; P = 0.005), and CD (OR 0.29; 95% CI 0.15-0.58; P = 0.005) were associated with the lack of effective vaccination. Two HBsAg-positive patients, including 1 under curative nucleoside/nucleotide analog treatment, had received 6 and 7 infliximab infusions, and 1 HCV RNA-positive subject had been receiving corticosteroid and azathioprine therapies for 12 and 33 months, respectively. No viral reactivation occurred in these patients.
  
  
  CONCLUSIONS
  The prevalence of HBV and HCV infection in French IBD patients is similar to that of the general population. While the ECCO recommends an effective HBV vaccination in IBD, half of the patients were not vaccinated. The nonvaccination risk factors identified in our study may allow targeted vaccination coverage.
authors.affiliation: Inserm, U954 and Department of Hepato-Gastroenterology, Nancy University Hospital, France.
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Chevaux
authors.forename: Abdelbasset
authors.initials: A
authors.lastname: Nani
authors.forename: Abderrahim
authors.initials: A
authors.lastname: Oussalah
authors.forename: Véronique
authors.initials: V
authors.lastname: Venard
authors.forename: Mouni
authors.initials: M
authors.lastname: Bensenane
authors.forename: Arthur
authors.initials: A
authors.lastname: Belle
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Gueant
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Bigard
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bronowicki
authors.forename: Laurent
authors.initials: L
authors.lastname: Peyrin-Biroulet
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005602:France / Q000453:epidemiology; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006526:Hepatitis C / Q000453:epidemiology* / Q000517:prevention & control; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D014761:Viral Hepatitis Vaccines